NPHP3 and normal pressure hydrocephalus: There are no clinical trials registered for use of Tolvaptan in patients with NPH and there is only one case report in which Tolvaptan is described for the treatment of NPHP3-related infantile NPH without an effect on the very rapid renal function decline in this specific severe case (Strong et al., 2018).